From her first days in the patent profession, Claire has been involved with many of the major innovations in the life sciences’ field. These have spanned immunology-related therapeutics, RNA therapeutics, synthetic biology and genetic diagnostics, including applications of bioinformatics. This continues as a partner of both the specialist HGF CRISPR and microbiome IP teams.
Claire has extensive experience of opposition and appeal proceedings at the European Patent Office, including both defending and opposing high profile patents which have attracted much interest beyond patent professionals. This has included patents from the early days of recombinant antibodies through to controversial patents arising from gene discovery and more recently, much publicised patents for gene-editing technologies.
Claire also has much experience of handling patent portfolios demanding inter-disciplinary input including in the fields of bioinformatics and medical and diagnostic devices. This has included much in the application of high-throughput nucleic acid sequencing technologies such as non-invasive foetal testing and cancer diagnostics.
As one of the most experienced patent partners’ of the life science team, Claire has the reputation of being able to apply creative thinking to turn around the most difficult IP problems. She has been responsible for building the IP portfolios of a number of companies and continues to enjoy the challenge of advising on freedom-to-operate and IP strategy.
MA(Oxon) Biochemistry with supplemental chemical pharmacology
PhD St George's Hospital Medical School
Accompanying quotes: a " fearless warrior"; "Claire pays meticulous attention to detail and has superb technical and scientific knowledge; clients can concentrate on their own growth knowing their IP is in safe hands."
May 10th 2022
March 23rd 2022
March 3rd 2020
November 21st 2019
June 27th 2019
June 3rd 2019
April 25th 2019
March 14th 2019
Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …Read article
After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …Event details
HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …Event details
HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …Event details
HGF Patent Attorney Dr Robert Weinert-Aplin is attending and speaking at the Manufacturing & Supply Chain Conference on 10th March 2022 in Milton Keynes, UK. The Manufacturing & Supply Chain …Event details
HGF Partner and Patent Attorney Craig Thomson and Patent Director Dr Jennifer Bailey write an article for The Microbiome Times on ELIGO v SNIPR: a reflection on IP strategies in …Read article
With news that the Austrian parliament has ratified the Protocol on the provisional application of the Agreement on a Unified Patent Court on 2 December 2021, the Unified Patent Court …Read article
One of the most often asked questions of patent attorneys is “when should we file?” Both timing and content of a first filing should be important strategic decisions. This is …Read article
If you would like to discuss how HGF could help you, contact one of our IP specialists.